knowledge -WSS

knowledge

author：knowledge 2025-10-02 22:39:56 - browse：65516

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： In Spain, a hospital brews its own CAR

WSS

U.K. Biobank has 500,000 peoples' genome sequences available

Violet CEO on training clinicians to promote more inclusive care

The EPA's new lead rule: How one expert crunched the numbers

Violet CEO on training clinicians to promote more inclusive care

J&J to emphasize cancer drugs, stop much of its vaccine research

SNAP should offer more nutrition education

focus

knowledge

entertainment

Medical records are filled with copy

Keeping primary care docs in field isn't impossible, says AAFP CEO

Activists slam private health insurers over coverage restrictions

J&J to emphasize cancer drugs, stop much of its vaccine research

Activists slam private health insurers over coverage restrictions

How to keep neuroscience’s past racism from being its future

Cancer drug shortages should be causing more outrage

Carvykti CAR

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Hospitals owned by private equity see complications spike 25%

Wikipedia

Albert Bourla of Pfizer: worst biopharma CEO of 2023

CRISPR gene editing developments we’re watching in 2024

Cigna, Humana reportedly in talks to merge

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Organ aging and disease risk measured by new blood test

How to keep neuroscience’s past racism from being its future

leisure time

hotspot

explore

hotspot